says
ok, I will go back and make sure you have access.
Be...
Well-Known Member
I agree with Dr.. Evil. My best guess is that monoclonal antibody cocktails will end up being more effective. Several are in Phase 3 trials and hopefully we find something soon. They have been carefully designed and you would know exactly what you are giving the patient. As for the plasma, there are so many variables and so hard to control. Evidence so far with that approach is not as encouraging as I was expecting. No proper clinical trials as yet and you might see very different effects depending on the donor.
What will get us back to normal is a safe and effective vaccine. Convalescent plasmas and infused monkclonal antibodies cannot provide more than transient protection, but I could imagine the antibody being administered in people who test positive on an outpatient basis.
Meanwhile, there are some very preliminary but encouraging results on a drug that mimics vasoactive intestinal peptide (VIP). This peptide seems to have a pretty strong effect on lung cells and lung blood vessels and it has been used in critically ill Covid-19 patients. Nothing
peer reviewed yet, so not to get too excited, but several patients on death's door here at Houston Methodist Hospital recovered after receiving it.
What will get us back to normal is a safe and effective vaccine. Convalescent plasmas and infused monkclonal antibodies cannot provide more than transient protection, but I could imagine the antibody being administered in people who test positive on an outpatient basis.
Meanwhile, there are some very preliminary but encouraging results on a drug that mimics vasoactive intestinal peptide (VIP). This peptide seems to have a pretty strong effect on lung cells and lung blood vessels and it has been used in critically ill Covid-19 patients. Nothing
peer reviewed yet, so not to get too excited, but several patients on death's door here at Houston Methodist Hospital recovered after receiving it.
Last edited: